Does the media refer more to VTRS or XENE?

In the previous week, Viatris had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Viatris' score of 0.54 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XENE or GMAB?

In the previous week, Genmab A/S had 6 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 8 mentions for Genmab A/S and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Genmab A/S's score of -0.04 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer XENE or ASND?

In the previous week, Ascendis Pharma A/S had 12 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Ascendis Pharma A/S's score of 0.73 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XENE or BBIO?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat BridgeBio Pharma's score of 0.26 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AXSM or XENE?

In the previous week, Axsome Therapeutics had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 5 mentions for Axsome Therapeutics and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.50 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Xenon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xenon Pharmaceuticals (XENE) Competitors

$60.36 +0.23 (+0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$61.04 +0.69 (+1.13%)

As of 04:44 PM Eastern

Compare

XENE vs. VTRS, GMAB, ASND, BBIO, and AXSM

Should you buy Xenon Pharmaceuticals stock or one of its competitors? MarketBeat compares Xenon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenon Pharmaceuticals include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Xenon Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 10.20%. Xenon Pharmaceuticals has a consensus target price of $77.20, suggesting a potential upside of 27.90%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Xenon Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.56B	1.27	-$3.51B	-$0.26	N/A
Xenon Pharmaceuticals	$7.50M	778.00	-$345.91M	-$4.70	N/A

79.9% of Viatris shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Viatris had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Viatris' score of 0.54 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Viatris on 11 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Genmab A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Genmab A/S had 6 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 8 mentions for Genmab A/S and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Genmab A/S's score of -0.04 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	778.00	-$345.91M	-$4.70	N/A
Genmab A/S	$3.90B	4.39	$963M	$1.32	20.81

Xenon Pharmaceuticals currently has a consensus target price of $77.20, suggesting a potential upside of 27.90%. Genmab A/S has a consensus target price of $37.93, suggesting a potential upside of 38.07%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has a net margin of 21.05% compared to Xenon Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Genmab A/S	21.05%	15.34%	8.94%

Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Summary

Genmab A/S beats Xenon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Xenon Pharmaceuticals currently has a consensus target price of $77.20, indicating a potential upside of 27.90%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 10.75%. Given Xenon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a net margin of 57.87% compared to Xenon Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ascendis Pharma A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	778.00	-$345.91M	-$4.70	N/A
Ascendis Pharma A/S	$814.57M	20.43	-$258M	$8.67	30.76

In the previous week, Ascendis Pharma A/S had 12 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Ascendis Pharma A/S's score of 0.73 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Xenon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Xenon Pharmaceuticals (NASDAQ:XENE) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	778.00	-$345.91M	-$4.70	N/A
BridgeBio Pharma	$502.08M	29.05	-$724.93M	-$3.74	N/A

Xenon Pharmaceuticals currently has a consensus target price of $77.20, indicating a potential upside of 27.90%. BridgeBio Pharma has a consensus target price of $92.90, indicating a potential upside of 24.73%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Xenon Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
BridgeBio Pharma	-124.42%	N/A	-65.81%

In the previous week, BridgeBio Pharma had 11 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat BridgeBio Pharma's score of 0.26 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

Xenon Pharmaceuticals beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

In the previous week, Axsome Therapeutics had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 5 mentions for Axsome Therapeutics and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat Axsome Therapeutics' score of 0.50 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Axsome Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
Xenon Pharmaceuticals	$7.50M	778.00	-$345.91M	-$4.70	N/A

Axsome Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Axsome Therapeutics presently has a consensus target price of $258.95, indicating a potential upside of 5.79%. Xenon Pharmaceuticals has a consensus target price of $77.20, indicating a potential upside of 27.90%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xenon Pharmaceuticals has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Xenon Pharmaceuticals' return on equity of -49.23% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Summary

Xenon Pharmaceuticals beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.84B	$3.63B	$6.76B	$12.60B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-12.84	21.26	27.33	24.88
Price / Sales	778.00	336.88	561.84	115.98
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	8.02	8.74	11.01	6.56
Net Income	-$345.91M	$23.81M	$3.57B	$336.70M
7 Day Performance	10.53%	3.64%	2.56%	3.31%
1 Month Performance	10.29%	1.64%	0.89%	1.68%
1 Year Performance	92.84%	69.47%	36.84%	31.96%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	3.7295 of 5 stars	$60.36 +0.4%	$77.20 +27.9%	+85.6%	$5.84B	$7.50M	N/A	210	Positive News
VTRS Viatris	2.8724 of 5 stars	$15.38 +0.1%	$17.50 +13.8%	+80.1%	$17.90B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.6781 of 5 stars	$25.61 +1.3%	$37.93 +48.1%	+26.9%	$15.76B	$3.72B	19.40	3,029	News Coverage Gap Up
ASND Ascendis Pharma A/S	4.255 of 5 stars	$228.00 -1.2%	$295.39 +29.6%	+53.1%	$14.40B	$865.78M	26.30	1,189
BBIO BridgeBio Pharma	3.1879 of 5 stars	$68.92 +4.0%	$91.05 +32.1%	+60.5%	$12.98B	$502.08M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Xenon Pharmaceuticals compare to Viatris?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Xenon Pharmaceuticals compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Xenon Pharmaceuticals compare to Viatris?

Do analysts recommend VTRS or XENE?

Which has more risk and volatility, VTRS or XENE?

Is VTRS or XENE more profitable?

Which has higher valuation and earnings, VTRS or XENE?

Do insiders and institutionals have more ownership in VTRS or XENE?

Does the media refer more to VTRS or XENE?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Do institutionals and insiders have more ownership in XENE or GMAB?

Does the media prefer XENE or GMAB?

Which has better valuation and earnings, XENE or GMAB?

Do analysts rate XENE or GMAB?

Is XENE or GMAB more profitable?

Which has more volatility and risk, XENE or GMAB?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Which has more volatility and risk, XENE or ASND?

Do analysts recommend XENE or ASND?

Is XENE or ASND more profitable?

Do insiders & institutionals believe in XENE or ASND?

Which has higher valuation & earnings, XENE or ASND?

Does the media prefer XENE or ASND?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Do institutionals & insiders hold more shares of XENE or BBIO?

Which has stronger earnings & valuation, XENE or BBIO?

Do analysts rate XENE or BBIO?

Is XENE or BBIO more profitable?

Does the media refer more to XENE or BBIO?

Which has more risk & volatility, XENE or BBIO?

Summary

How does Xenon Pharmaceuticals compare to Axsome Therapeutics?

Does the media favor AXSM or XENE?

Do institutionals and insiders believe in AXSM or XENE?

Which has better valuation and earnings, AXSM or XENE?

Which has more volatility and risk, AXSM or XENE?

Do analysts prefer AXSM or XENE?

Is AXSM or XENE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools